0001493152-24-029227.txt : 20240726 0001493152-24-029227.hdr.sgml : 20240726 20240726160514 ACCESSION NUMBER: 0001493152-24-029227 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240722 ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240726 DATE AS OF CHANGE: 20240726 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TNF Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001321834 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36268 FILM NUMBER: 241146798 BUSINESS ADDRESS: STREET 1: 855 N. WOLFE STREET STREET 2: SUITE 601 CITY: BALTIMORE STATE: MD ZIP: 21205 BUSINESS PHONE: 856-848-8698 MAIL ADDRESS: STREET 1: 855 N. WOLFE STREET STREET 2: SUITE 601 CITY: BALTIMORE STATE: MD ZIP: 21205 FORMER COMPANY: FORMER CONFORMED NAME: MyMD Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20210420 FORMER COMPANY: FORMER CONFORMED NAME: Akers Biosciences, Inc. DATE OF NAME CHANGE: 20170413 FORMER COMPANY: FORMER CONFORMED NAME: Akers Biosciences Inc DATE OF NAME CHANGE: 20050325 8-K 1 form8-k.htm
false --12-31 0001321834 0001321834 2024-07-22 2024-07-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 22, 2024

 

TNF Pharmaceuticals, Inc.

(Exact name of Registrant as specified in its charter)

 

Delaware   001-36268   22-2983783
(State or other jurisdiction
of incorporation)		   (Commission
File No.)		   (IRS Employer
Identification No.)

 

855 N. Wolfe Street, Suite 623    
Baltimore, MD   21205
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (856) 848-8698

 

MyMD Pharmaceuticals, Inc.

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities Registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, par value $0.001 per share   TNFA   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

On July 22, 2024, TNF Pharmaceuticals, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Certificate of Incorporation (the “Certificate of Amendment”) to change the name of the Company from “MyMD Pharmaceuticals, Inc.” to “TNF Pharmaceuticals, Inc.”, effective as of July 22, 2024 (the “Name Change”). In addition, effective before the open of market trading on July 24, 2024, the Company’s common stock ceased trading under the ticker symbol “MYMD” and began trading on the Nasdaq Stock Market under the ticker symbol “TNFA” (“Symbol Change”).

 

The Name Change does not affect the rights of the Company’s security holders. There will be no change to the Company’s CUSIP in connection with the Name Change.

 

Pursuant to Section 242 of the Delaware General Corporation Law, stockholder approval was not required to complete the Name Change or to approve or effect the Certificate of Amendment. The information set forth herein is qualified in its entirety by reference to the complete text of the Certificate of Amendment, a copy of which is filed with this report as Exhibit 3.1 and is incorporated by reference herein.

 

Item 7.01. Regulation FD Disclosure.

 

On July 22, 2024, the Company issued a press release announcing the Name Change. A copy of the press release is furnished hereto as Exhibit 99.1 and incorporated by reference herein.

 

On July 24, 2024, the Company issued a press release announcing the Symbol Change. A copy of the press release is furnished hereto as Exhibit 99.2 and incorporated by reference herein.

 

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by reference in such a filing. Furthermore, the furnishing of information under Item 7.01 of this Current Report on Form 8-K is not intended to constitute a determination by the Company that the information contained herein, including the exhibits hereto, is material or that the dissemination of such information is required by Regulation FD.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit Number   Description
3.1   Certificate of Amendment of Certificate of Incorporation of TNF Pharmaceuticals, Inc.
99.1   Press Release, dated July 22, 2024.
99.2   Press Release, dated July 24, 2024.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  TNF PHARMACEUTICALS, INC.
     
Date: July 26, 2024 By: /s/ Joshua Silverman                  
  Name: Joshua Silverman
  Title: Director

 

 

 

 EX-3.1 2 ex3-1.htm

 

Exhibit 3.1

 

Certificate of Amendment
of
Certificate of Incorporation
of
MYMD PHARMACEUTICALS, INC.

 

MyMD Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”) hereby certifies:

 

1.The original Certificate of Incorporation of the Corporation was filed with the Secretary of State of Delaware on October 19, 2023 (the “Certificate of Incorporation”).
   
2.The Certificate of Incorporation was corrected by the Certificate of Correction thereto, filed with the Secretary of State of Delaware on March 25, 2024.
   
3.Resolutions were duly adopted by the Board of Directors of the Corporation setting forth this proposed amendment to the Certificate of Incorporation.
   
4.Article I of the Certificate of Incorporation is hereby amended and restated in its entirety to read as follows:

 

“The name of the corporation is TNF Pharmaceuticals, Inc. (hereinafter referred to as the “Corporation”).

 

5.The foregoing amendment was duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware.
   
6.The effective date of this Certificate of Amendment to the Certificate of Incorporation shall be July 22, 2024.

 

[Signature page follows.]

 

 
 

 

IN WITNESS WHEREOF, said corporation has caused this Certificate of Amendment to be executed this 22nd day of July, 2024.

 

  MyMD Pharmaceuticals, Inc.
     
  By: /s/ Mitchell Glass                         
  Name: Mitchell Glass, M.D.
  Title: President and Chief Medical Officer

 

 

 

 

 EX-99.1 3 ex99-1.htm

 

Exhibit 99.1

 

MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc.

 

New name represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system

 

Company plans mid-stage clinical trials of TNF-alpha inhibitor drug MYMD-1® following statistically significant Phase 2 studies

 

TNF Pharmaceuticals will begin trading on Nasdaq under the new trading symbol “TNFA” effective July 24, 2024

 

BALTIMORE — July 22, 2024 — TNF Pharmaceuticals, Inc., formerly MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflammatory conditions, today announced a rebranding to the new name “TNF Pharmaceuticals, Inc.,” effective today. The Company’s common stock, listed on the Nasdaq Capital Market, will begin trading under the new stock symbol “TNFA,” effective before the market open on Wednesday, July 24, 2024.

 

“Our new name, TNF Pharmaceuticals, is more closely aligned with our scientific focus on TNF-alpha, a protein in the body that plays a key role in inflammation and autoimmunity,” said the Company’s President and Chief Medical Officer Mitchell Glass, M.D. “Excess TNF-α in the blood or tissue can lead to diseases and disorders marked by acute or chronic inflammation, including age-related disorders. Our lead clinical candidate, MYMD-1®, blocks the activity of excess TNF-alpha which supports restoration of control and regulation of the immune system.”

 

MYMD-1 is a novel, orally dosed TNF-alpha (TNF-α) inhibitor drug for treating multiple conditions related to immune-metabolic dysregulation. A successful and statistically significant small Phase 2 study was completed in 2023, evaluating the safety and efficacy of MYMD-1 as a treatment for sarcopenia, the progressive loss of muscle mass and strength associated with aging.

 

“We are moving forward with mid-stage clinical trials of MYMD-1 in sarcopenia based on positive clinical data from our Phase 2 trial and previous research findings,” Dr. Glass continued. “We believe MYMD-1 could become a transformative treatment for TNF-alpha-based autoimmune and inflammatory diseases including age-related conditions.”

 

MYMD-1 is distinguished from currently marketed TNF-α blockers in multiple ways. It is a first-in-class oral treatment shown to reduce TNF-α and inflammation without infusion or injection. The drug’s ease of oral dosing is a strong advantage over currently available TNF-α blockers, none of which are dosed orally. Unlike systemic therapies, our oral TNF alpha inhibitor can be dose adjusted acutely and chronically for maximal safety and efficacy depending on the patient’s need.

 

 
 

 

TNF Pharmaceuticals retains the registered trademark MYMD-1® for its lead drug program. The Company’s new Investors website address is ir.tnfpharma.com.

 

About TNF Pharmaceuticals, Inc.

 

TNF Pharmaceuticals, Inc., formerly known as MyMD Pharmaceuticals, Inc., a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. MYMD-1® is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs.

 

Cautionary Statement Regarding Forward-Looking Statements

 

This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and neither the Company nor its affiliates assume any duty to update forward-looking statements. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “may,” “plan,” “will,” “would’’ and other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: the Company’s ability to maintain compliance with the Nasdaq Stock Market’s listing standards; the timing of, and the Company’s ability to, obtain and maintain regulatory approvals for clinical trials of the Company’s pharmaceutical candidates; the timing and results of the Company’s planned clinical trials for its pharmaceutical candidates; the amount of funds the Company requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which the Company operates; the Company’s ability to retain and attract senior management and other key employees; the Company’s ability to quickly and effectively respond to new technological developments; and the Company’s ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the Company’s proprietary rights. A discussion of these and other factors with respect to the Company is set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed by the Company on April 1, 2024, and subsequent reports that the Company files with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Investor Contact:

 

Robert Schatz
(646) 421-9523
rschatz@tnfpharma.com

 

 

 

 EX-99.2 4 ex99-2.htm

 

Exhibit 99.2

 

TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol “TNFA” Effective Before Market Open Today

 

New name and stock symbol represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system

 

BALTIMORE — July 24, 2024 — TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (formerly MyMD Pharmaceuticals, Inc.) (the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflammatory conditions, today announced that its common stock, listed on the Nasdaq Capital Market, begins trading under the new ticker symbol, “TNFA,” effective before the market open today, July 24, 2024.

 

The new trading symbol “TNFA” replaces the Company’s previous trading symbol “MYMD” and coincides with the Company’s previously announced corporate name change to TNF Pharmaceuticals, Inc. The new corporate identity more accurately aligns with the Company’s scientific focus on TNF-alpha (TNF-alpha tumor necrosis factor-alpha, or TNF-α), a protein in the body that plays a key role in inflammation and autoimmunity. The Company’s lead clinical candidate, MYMD-1®, blocks the activity of excess TNF-α, which supports restoration of control and regulation of the immune system.

 

“Our Company’s new name and stock identity comes at an important time in our clinical development of MYMD-1, illuminating both our core science and our clinical candidate’s strong potential to be the first TNF-α inhibitor in this indication,” said the Company’s President, Chief Medical Officer and Director, Mitchell Glass, M.D.

 

Effective today, all stock trading, Securities and Exchange Commission filings and market-related information will be reported under the new trading symbol “TNFA.” The CUSIP for the Company’s common stock is unchanged. There is no action required by the Company’s current stockholders with respect to the trading symbol change.

 

About TNF Pharmaceuticals, Inc.

 

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA), formerly known as MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. MYMD-1® is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs. For more information, visit www.tnfpharma.com.

 

 
 

 

Cautionary Statement Regarding Forward-Looking Statements

 

This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and neither the Company nor its affiliates assume any duty to update forward-looking statements. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “may,” “plan,” “will,” “would’’ and other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: the Company’s ability to maintain compliance with the Nasdaq Stock Market’s listing standards; the timing of, and the Company’s ability to, obtain and maintain regulatory approvals for clinical trials of the Company’s pharmaceutical candidates; the timing and results of the Company’s planned clinical trials for its pharmaceutical candidates; the amount of funds the Company requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which the Company operates; the Company’s ability to retain and attract senior management and other key employees; the Company’s ability to quickly and effectively respond to new technological developments; and the Company’s ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the Company’s proprietary rights. A discussion of these and other factors with respect to the Company is set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed by the Company on April 1, 2024, and subsequent reports that the Company files with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Investor Contact:

 

Robert Schatz
(646) 421-9523
rschatz@tnfpharma.com
www.tnfpharma.com

 

 

 

 

 EX-101.SCH 5 tnfa-20240722.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 6 tnfa-20240722_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Information, Former Legal or Registered Name EX-101.PRE 7 tnfa-20240722_pre.xml XBRL PRESENTATION FILE XML 9 R1.htm IDEA: XBRL DOCUMENT v3.24.2
Cover
Jul. 22, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 22, 2024
Current Fiscal Year End Date --12-31
Entity File Number 001-36268
Entity Registrant Name TNF Pharmaceuticals, Inc.
Entity Central Index Key 0001321834
Entity Tax Identification Number 22-2983783
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 855 N. Wolfe Street
Entity Address, Address Line Two Suite 623
Entity Address, City or Town Baltimore
Entity Address, State or Province MD
Entity Address, Postal Zip Code 21205
City Area Code (856)
Local Phone Number 848-8698
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.001 per share
Trading Symbol TNFA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Information, Former Legal or Registered Name MyMD Pharmaceuticals, Inc.
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2 html 1 25 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://mymd.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm tnfa-20240722.xsd tnfa-20240722_lab.xml tnfa-20240722_pre.xml http://xbrl.sec.gov/dei/2024 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "TNFA", "nsuri": "http://mymd.com/20240722", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "tnfa-20240722.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "labelLink": { "local": [ "tnfa-20240722_lab.xml" ] }, "presentationLink": { "local": [ "tnfa-20240722_pre.xml" ] } }, "keyStandard": 25, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2024": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 60, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 25 }, "report": { "R1": { "role": "http://mymd.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-07-22", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-07-22", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationFormerLegalOrRegisteredName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInformationFormerLegalOrRegisteredName", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Information, Former Legal or Registered Name", "documentation": "Former Legal or Registered Name of an entity" } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://mymd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001493152-24-029227-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-029227-xbrl.zip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end XML 18 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001321834 2024-07-22 2024-07-22 iso4217:USD shares iso4217:USD shares false --12-31 0001321834 8-K 2024-07-22 TNF Pharmaceuticals, Inc. DE 001-36268 22-2983783 855 N. Wolfe Street Suite 623 Baltimore MD 21205 (856) 848-8698 MyMD Pharmaceuticals, Inc. false false false false Common stock, par value $0.001 per share TNFA NASDAQ false